Mo, good post and agreed 100%. I believe this is t
Post# of 72444
Quote:
”A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
http://www.ipharminc.com/press-release/2018/1...priorities


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
